

Derma  
Consult  
GmbH

Gesellschaft zur Prüfung von  
Dermatika

DC Brunnenstraße 61 53347 Alfter Germany

Phone: +49 - (0)2222 / 9108 - 10  
Fax: +49 - (0)2222 / 9108 - 40  
E-mail: info@dermaconsult.com  
Web: www.dermaconsult.com  
Date: 07.02.2020

## Expertise

Examination of the Product

**“Sansin Hand and Body Balm”**

*batch number: 01092020*

*Concentration: undiluted*

by Human Patch Test (Cosmetic Trial)

*Sponsor*

**Sansin Globe Zrt.**

Ady Endre u. 19/a  
Budapest  
Hungary

*Performing Laboratory*

**Derma Consult GmbH**

Brunnenstr. 61  
53347 Alfter  
Germany

## Study Details

*Type of study.....:* Determination of irritating effects to the skin with an occlusive patch test.  
*Study Period.....:* February 2020  
*Study Director.....:* Dr. med. H. Prieur  
*Test subjects.....:* 50 (20-72 years; sex distribution non-standardized)  
28 normal healthy, 2 eczema, 1 allergy and 19 subjects with sensitive skin  
*Test site.....:* Back  
*Concentration.....:* Undiluted  
*Controls.....:* SDS (1% in water), water


## Summary Results

All participants completed the study. Under the test conditions, SDS (1% in water) caused positive reactions in 23 subjects. The negative control water showed no reactions. None of the subjects showed any reaction to the test product. On the basis of the test results and under the test conditions, the product


**“Sansin Hand and Body Balm“**

is to be classified as 'harmless' as regards the possibility of skin irritation.

Signature:

  
Dr. med. H. Prieur  
Dermatologist - Allergist

Signature:

  
Dr. J. Nissen  
Pharmacist - M.D.R.A.

Page 1 of 3

manager: Dr. Hans-Peter Nissen Dr. Jana Nissen  
VAT-REG.No. DE 123369725

district court Bonn HRB 5272  
Tax No. 222/5703/0374

## **Methodology**

### ***Introduction***

The purpose of the photo patch test is to determine skin sensitivity to irradiated products. It allows to assess the photo toxic potential of cosmetic-finished products and raw materials.

### ***Description***

All the work described in this expertise was conducted considering the guidelines by COLIPA (Walker A.P. et al: Test Guidelines for Assessment of Skin Compatibility of Cosmetic Finished Products in Man. Food and Chemical Toxicology 34, 1996, 651-660; COSMETICS EUROPE: Product test guidelines for the assessment of human skin compatibility 1997).

Because it was a study with humans, it was carried out taking into account the principle requirements of the Declaration of Helsinki (1964) and subsequent revisions.

Experiments were carried out on 50 volunteers (28 normal healthy subjects, 2 eczema patients, 1 allergy patients, 19 subjects with sensitive skin) between the ages of 20 to 72. Sex distribution was not standardized. The volunteers were clearly informed, verbally and in writing, regarding the nature of the study, the timetable, constraints and possible risks. They gave their written informed consent before participating in the study.

Participants could withdraw from the study at any time without giving reason. During the test period, the subjects refrained from using other substances on the test areas.

### ***Inclusion criteria***

- informed volunteers
- age  $\geq$  18 years

### ***Exclusion criteria***

- pregnant or lactating women
- blemishes or marks (tattoos, sunburn) which interfere with scoring
- any skin disease that may interfere with the aim of the study

### ***Procedure***

The product was applied in a concentration as outlined above in square test-chambers (allergEAZE<sup>®</sup> clear Patch Test Chambers; SmartPractice<sup>®</sup>, Phoenix, AZ) to the backs of the panellists in duplicate as parallel series on either side of the back for 24 hours. Treatment sites were assessed for the presence of irritations 30 minutes after the removal of the occlusion. Then one of the two test areas was irradiated with UV-A light in a dose of 5J/cm<sup>2</sup>.

The treatment sites were again assessed for the presence of irritation by a trained evaluator using a 5 point visual scoring scale at 24 and 48 hours after the irradiation.

### ***Scoring scale***

Erythema 0: no E., 1: slight E., 2: significant E., 3: pronounced E., 4: strong E.

Fissure 0: no F., 1: minimal F., 2: significantly perceptible F., 3: pronounced F., 4: ulceration

Scaling 0: no Sc., 1: minimal Sc., 2: moderate Sc., 3: significant Sc., 4: closed scale crust

### **Results**

The test results outlining the data for erythema, scaling and fissure formation on a per subject base for the test product are attached in tabulated form.

### **Literature**

*Magnus Lindberg and Mihaly Matura:*

“Patch Testing” in

J. D. Johansen, P.J. Frosch, J.-P. Lepoittevin (Eds.),

Contact Dermatitis 5<sup>th</sup> Edition

Springer-Verlag, Berlin Heidelberg, Germany (2011), pp. 439-464

*J-M. Lachapelle, H. I. Maibach:*

“Patch Testing and Prick Testing - A practical Guide

Official Publication of the ICDRG“

Third Edition

Springer-Verlag, Berlin Heidelberg, Germany (2012)

***Appendix:*** test protocol

No.	Type	after 48 h			after 72 h		
		E	F	S	E	F	S
1	S	0	0	0	0	0	0
2	S	0	0	0	0	0	0
3		0	0	0	0	0	0
4	S	0	0	0	0	0	0
5		0	0	0	0	0	0
6		0	0	0	0	0	0
7	S	0	0	0	0	0	0
8		0	0	0	0	0	0
9		0	0	0	0	0	0
10		0	0	0	0	0	0
11	S	0	0	0	0	0	0
12	S	0	0	0	0	0	0
13		0	0	0	0	0	0
14	A	0	0	0	0	0	0
15		0	0	0	0	0	0
16	S	0	0	0	0	0	0
17		0	0	0	0	0	0
18		0	0	0	0	0	0
19	S	0	0	0	0	0	0
20		0	0	0	0	0	0
21		0	0	0	0	0	0
22		0	0	0	0	0	0
23	S	0	0	0	0	0	0
24	S	0	0	0	0	0	0
25	S	0	0	0	0	0	0
26		0	0	0	0	0	0
27	S	0	0	0	0	0	0
28	E	0	0	0	0	0	0
29	E	0	0	0	0	0	0
30		0	0	0	0	0	0
31	S	0	0	0	0	0	0
32	S	0	0	0	0	0	0
33		0	0	0	0	0	0
34		0	0	0	0	0	0
35	S	0	0	0	0	0	0
36		0	0	0	0	0	0
37		0	0	0	0	0	0
38		0	0	0	0	0	0
39	S	0	0	0	0	0	0
40		0	0	0	0	0	0
41		0	0	0	0	0	0
42		0	0	0	0	0	0
43	S	0	0	0	0	0	0
44		0	0	0	0	0	0
45		0	0	0	0	0	0
46	S	0	0	0	0	0	0
47		0	0	0	0	0	0
48		0	0	0	0	0	0
49		0	0	0	0	0	0
50	S	0	0	0	0	0	0
SUM		0,0	0,0	0,0	0,0	0,0	0,0

Erythema (E): no E.: 0, slight E.: 1, clear E.: 2, severe E.: 3, very severe E.: 4  
 Fissures (F): no F.: 0, minimal F.: 1, clearly visible F.: 2, distinct F.: 3, ulceration: 4  
 Scales (S): no S.: 0, minimal S.: 1, clearly visible S.: 2, moderate S.: 3, distinct S.: 4

S: subjects with sensitive skin  
 E: patients with eczema  
 A: patients with allergy

No.	Type	after 48 h			after 72 h		
		E	F	S	E	F	S
1	S	0	0	0	0	0	0
2	S	0	0	0	0	0	0
3		0	0	0	0	0	0
4	S	0	0	0	0	0	0
5		0	0	0	0	0	0
6		0	0	0	0	0	0
7	S	0	0	0	0	0	0
8		0	0	0	0	0	0
9		0	0	0	0	0	0
10		0	0	0	0	0	0
11	S	0	0	0	0	0	0
12	S	0	0	0	0	0	0
13		0	0	0	0	0	0
14	A	0	0	0	0	0	0
15		0	0	0	0	0	0
16	S	0	0	0	0	0	0
17		0	0	0	0	0	0
18		0	0	0	0	0	0
19	S	0	0	0	0	0	0
20		0	0	0	0	0	0
21		0	0	0	0	0	0
22		0	0	0	0	0	0
23	S	0	0	0	0	0	0
24	S	0	0	0	0	0	0
25	S	0	0	0	0	0	0
26		0	0	0	0	0	0
27	S	0	0	0	0	0	0
28	E	0	0	0	0	0	0
29	E	0	0	0	0	0	0
30		0	0	0	0	0	0
31	S	0	0	0	0	0	0
32	S	0	0	0	0	0	0
33		0	0	0	0	0	0
34		0	0	0	0	0	0
35	S	0	0	0	0	0	0
36		0	0	0	0	0	0
37		0	0	0	0	0	0
38		0	0	0	0	0	0
39	S	0	0	0	0	0	0
40		0	0	0	0	0	0
41		0	0	0	0	0	0
42		0	0	0	0	0	0
43	S	0	0	0	0	0	0
44		0	0	0	0	0	0
45		0	0	0	0	0	0
46	S	0	0	0	0	0	0
47		0	0	0	0	0	0
48		0	0	0	0	0	0
49		0	0	0	0	0	0
50	S	0	0	0	0	0	0
<b>SUM</b>		0,0	0,0	0,0	0,0	0,0	0,0

Erythema (E): no E.: 0, slight E.: 1, clear E.: 2, severe E.: 3, very severe E.: 4  
 Fissures (F): no F.: 0, minimal F.: 1, clearly visible F.: 2, distinct F.: 3, ulceration: 4  
 Scales (S): no S.: 0, minimal S.: 1, clearly visible S.: 2, moderate S.: 3, distinct S.: 4

S: subjects with sensitive skin  
 E: patients with eczema  
 A: patients with allergy

No.	Type	after 48 h			after 72 h		
		E	F	S	E	F	S
1	S	1	0	1	1	0	1
2	S	1	0	0	1	0	0
3		1	0	0	0	0	0
4	S	2	0	1	2	0	1
5		0	0	0	0	0	0
6		0	0	0	0	0	0
7	S	1	0	1	1	0	1
8		0	0	0	0	0	0
9		1	0	0	1	0	0
10		0	0	0	0	0	0
11	S	2	0	0	2	0	0
12	S	1	0	0	1	0	0
13		0	0	0	0	0	0
14	A	0	0	0	0	0	0
15		0	0	0	0	0	0
16	S	2	0	0	2	0	0
17		0	0	0	0	0	0
18		1	0	0	0	0	0
19	S	1	0	0	0	0	0
20		0	0	0	0	0	0
21		0	0	0	0	0	0
22		0	0	0	0	0	0
23	S	1	0	0	0	0	0
24	S	0	0	0	0	0	0
25	S	1	0	0	1	0	0
26		0	0	0	0	0	0
27	S	0	0	0	0	0	0
28	E	2	0	2	2	0	2
29	E	1	0	1	1	0	1
30		0	0	0	0	0	0
31	S	0	0	0	0	0	0
32	S	0	0	0	0	0	0
33		0	0	0	0	0	0
34		0	0	0	0	0	0
35	S	1	0	1	1	0	0
36		0	0	0	0	0	0
37		0	0	0	0	0	0
38		1	0	0	1	0	0
39	S	1	0	0	0	0	0
40		0	0	0	0	0	0
41		0	0	0	0	0	0
42		0	0	0	1	0	0
43	S	0	0	0	0	0	0
44		1	0	0	1	0	0
45		0	0	0	0	0	0
46	S	1	0	0	0	0	0
47		0	0	0	0	0	0
48		1	0	0	0	0	0
49		0	0	0	0	0	0
50	S	1	0	1	1	0	1
SUM		0,52	0,0	0,16	0,4	0,0	0,14

Erythema (E): no E.: 0, slight E.: 1, clear E.: 2, severe E.: 3, very severe E.: 4  
 Fissures (F): no F.: 0, minimal F.: 1, clearly visible F.: 2, distinct F.: 3, ulceration: 4  
 Scales (S): no S.: 0, minimal S.: 1, clearly visible S.: 2, moderate S.: 3, distinct S.: 4

S: subjects with sensitive skin  
 E: patients with eczema  
 A: patients with allergy